Dupilumab: a delayed response in asthmatic and atopic patients treated for chronic rhinosinusitis with nasal polyps
European Archives of Oto-Rhino-Laryngology · 2024
DOI: 10.1007/s00405-024-08738-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2024. Verfasst von Umberto Tanzini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Head and Neck Department, Otorhinolaryngology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Nasal Polyps, Antibodies, Monoclonal, Humanized, Sinusitis, Rhinitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università della Svizzera italiana.
Abstract (Originalsprache)
Purpose Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a common disease, which was previously approached with sinus surgery or systemic corticosteroids. The advent of biological therapies radically changed the approach to this disease. On the other hand, there is scarce scientific evidence of how specific subsets of patients respond to this treatment. Methods this is a monocentric, prospective study investigating the long-term efficacy on biweekly 300 mg dupilumab therapy in CRSwNP, prescribed to 61 patients. Patients were evaluated at baseline and every 2 months for the first 6 months, then at 9, 12, 16, 20 and 24 months. Results dupilumab proved to be an effective treatment, neatly improving both subjective and objective measurements in CRSwNP. The main finding of the study is the difference between specific subgroups of patients: while the overall response is similar, patients with Th2 comorbidities such as asthma and atopy tend to reach a stable response later, with the improvement ongoing even after 6 months of therapy, while non-asthmatic, non-atopic patients attain an earlier stability in response. Conclusions dupilumab provides an excellent long-term control of CRSwNP, but the response in asthmatic and atopic patients appears to be different and delayed when compared to non asthmatic and non atopic ones.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Head and Neck Department, Otorhinolaryngology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
- Otorhinolaryngology and Skull Base Center, AP-HP, Hospital Lariboisière, Paris, France.
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, 20132, Milan, Italy.
- Department of Otolaryngology-Head and Neck Surgery, Ente Ospedaliero Cantonale, Ospedale Regionale di Lugano, Lugano, Switzerland. matteotrimarchi@gmail.com.
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland. matteotrimarchi@gmail.com.
Förderung
- Università della Svizzera italiana
Zitieren
APA
Tanzini, U., Rampi, A., Vinciguerra, A., Danè, G., Yacoub, M. R., Bussi, M., & Trimarchi, M. (2024). Dupilumab: a delayed response in asthmatic and atopic patients treated for chronic rhinosinusitis with nasal polyps. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08738-2
Vancouver
Tanzini U, Rampi A, Vinciguerra A, Danè G, Yacoub MR, Bussi M, et al. Dupilumab: a delayed response in asthmatic and atopic patients treated for chronic rhinosinusitis with nasal polyps. European Archives of Oto-Rhino-Laryngology. 2024. doi:10.1007/s00405-024-08738-2
BibTeX
@article{Tanzini2024,
author = {Tanzini, Umberto and Rampi, Andrea and Vinciguerra, Alessandro and Danè, Giulia and Yacoub, Mona Rita and Bussi, Mario and Trimarchi, Matteo},
title = {Dupilumab: a delayed response in asthmatic and atopic patients treated for chronic rhinosinusitis with nasal polyps},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2024},
doi = {10.1007/s00405-024-08738-2}
}
EUVIMED